Transcription factors that interact with p53 and Mdm2

International Journal of Cancer

Volumn 138, Issue 7, 2016, Pages 1577-1585

  Inoue, Kazushi ^a   Fry, Elizabeth A ^a   Frazier, Donna P ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

apoptosis; Arf; cancer; Dmp1 (Dmtf1); E2F1; Mdm2; p53; polycomb; transcription factor; YB 1; YY1

Indexed keywords

PROTEIN MDM2; PROTEIN P53; TRANSCRIPTION FACTOR;

ANIMAL; CARCINOGENESIS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; TRANSCRIPTION INITIATION;

ANIMALS; CARCINOGENESIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84955574612     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29663     Document Type: Review

References (85)

1. Vousden KH, Prives C., Blinded by the light: the growing complexity of p53. Cell 2009; 137: 413-31.
2. Menendez D, Inga A, Resnick MA., The expanding universe of p53 targets. Nat Rev Cancer 2009; 9: 724-37.
3. Kruse J-P, Gu W., Modes of p53 regulation. Cell 2009; 137: 609-22.
4. Manfredi JJ., The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev 2010; 24: 1580-9.
5. Eischen CM, Lozano G., The Mdm network and its regulation of p53 activities: a rheostat of cancer risk. Hum Mutat 2014; 35: 728-37.
6. Brosh R, Rotter V., When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009; 9: 701-13.
7. Vaughan C, Pearsall I, Yeudall A, et al., p53: its mutations and their impact on transcription. Subcell Biochem 2014; 85: 71-90.
8. Lowe SW, Sherr CJ., Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev 2003; 13: 77-83.
9. Sherr CJ, Bertwistle D, Den Besten W, et al., p53-dependent and -independent functions of the Arf tumor suppressor. Cold Spring Harb Symp Quant Biol 2005; 70: 129-37.
10. Saporita AJ, Maggi LB, Jr, Apicelli AJ, et al., Therapeutic targets in the ARF tumor suppressor pathway. Curr Med Chem 2007; 14: 1815-27.
11. Ozenne P, Eymin B, Brambilla E, et al., The ARF tumor suppressor: structure, functions and status in cancer. Int J Cancer 2010; 127: 2239-47.
12. Maggi LB, Jr, Winkeler CL, Miceli AP, et al., ARF tumor suppression in the nucleolus. Biochim Biophys Acta 2014; 1842: 831-9.
13. Kamijo T, Zindy F, Roussel MF, et al., Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997; 91: 649-59.
14. Kamijo T, Bodner S, van de Kamp E, et al., Tumor spectrum in ARF-deficient mice. Cancer Res 1999; 59: 2217-22.
15. Hirai H, Sherr CJ., Interaction of D-type cyclins with a novel myb-like transcription factor DMP1. Mol Cell Biol 1996; 16: 6457-67.
16. Inoue K, Sherr CJ., Gene expression and cell cycle arrest mediated by transcription factor DMP1 is antagonized by D-type cyclins through a cyclin-dependent-kinase-independent mechanism. Mol Cell Biol 1998; 18: 1590-600.
17. Inoue K, Roussel MF, Sherr CJ., Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. Proc Natl Acad Sci USA 1999; 96: 3993-8.
18. Inoue K, Mallakin A, Frazier DP., Dmp1 and tumor suppression. Oncogene 2007; 26: 4329-35.
19. Aguilo F, Zhou MM, Walsh MJ., Long noncoding RNA, polycomb, and the ghosts haunting INK4b-ARF-INK4a expression. Cancer Res 2011; 71: 5365-9.
20. Iaquinta PJ, Lees JA., Life and death decisions by the E2F transcription factors. Curr Opin Cell Biol 2007; 19: 649-57.
21. Chen HZ, Tsai SY, Leone G., Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer 2009; 9: 785-97.
22. Benevolenskaya EV, Frolov MV., Emerging Links between E2F Control and Mitochondrial Function. Cancer Res 2015; 75: 619-23.
23. Kurimchak A, Graña X., PP2A: more than a reset switch to activate pRB proteins during the cell cycle and in response to signaling cues. Cell Cycle 2015; 14: 18-30.
24. Zhang Y, Zhang A, Shen C, et al., E2F1 acts as a negative feedback regulator of c-Myc-induced hTERT transcription during tumorigenesis. Oncol Rep 2014; 32: 1273-80.
25. Mallakin A, Taneja P, Matise LA, et al., Expression of Dmp1 in specific differentiated, nonproliferating cells and its repression by E2Fs. Oncogene 2006; 25: 7703-13.
26. Kohno K, Izumi H, Uchiumi T, et al., The pleiotropic functions of the Y-box-binding protein, YB-1. BioEssays 2003; 25: 691-8.
27. Okamoto T, Izumi H, Imamura T, et al., Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression. Oncogene 2000; 19: 6194-202.
28. Gordon S, Akopyan G, Garban H, et al., Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 2006; 25: 1125-42.
29. Zhang Q, Stovall DB, Inoue K, et al., The Oncogenic Role of Yin Yang 1. Crit Rev Oncogenesis 2011; 16: 163-97.
30. Sui G, Affar el B, Shi Y, et al., Yin Yang 1 is a negative regulator of p53. Cell 2004; 117: 859-72.
31. Frazier DP, Kendig RD, Kai F, et al., Dmp1 physically interacts with p53 and positively regulates p53's stabilization, nuclear localization, and function. Cancer Res 2012; 72: 1740-50.
32. Mallakin A, Sugiyama T, Taneja P, et al., Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer. Cancer Cell 2007; 12: 381-94.
33. Inoue K, Sugiyama T, Taneja P, et al., Emerging roles of DMP1 in lung cancer. Cancer Res 2008; 68: 4487-90.
34. Maglic D, Zhu S, Fry EA, et al., Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer. Oncogene 2013; 32: 4120-9.
35. Sreeramaneni R, Chaudhry A, McMahon M, et al., Ras-Raf-Arf signaling critically depends on the Dmp1 transcription factor. Mol Cell Biol 2005; 25: 220-32.
36. Taneja P, Maglic D, Kai F, et al., Critical role of Dmp1 in HER2/neu-p53 signaling and breast carcinogenesis. Cancer Res 2010; 70: 9084-94.
37. Taneja P, Mallakin A, Matise LA, et al., Repression of Dmp1 and Arf promoter by anthracyclins: critical roles of the NF-κB subunit p65. Oncogene 2007; 26: 7457-66.
38. Inoue K, Wen R, Rehg JE, et al., Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, ras transformation, and tumorigenesis. Genes Dev 2000; 14: 1797-809.
39. Inoue K, Zindy F, Randle DH, et al., Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas. Genes Dev 2001; 15: 2934-39.
40. Zhu S, Mott RT, Fry EA, et al., Cooperation between cyclin D1 expression and Dmp1-loss in breast cancer. Am J Pathol 2013; 183: 1339-50.
41. Fry EA, Taneja P, Maglic D, et al., Dmp1α inhibits HER2/neu-induced mammary tumorigenesis. PLoS One 2013; 8: e77870.
42. Mallakin A, Sugiyama T, Kai F, et al., The Arf-inducing transcription factor Dmp1 encodes transcriptional activator of amphiregulin, thrombospondin-1, JunB and Egr1. Int J Cancer 2010; 126: 1403-16.
43. Maglic D, Stovall DB, Cline JM, et al., DMP1β, a splice isoform of the tumor suppressor DMP1 locus, induces proliferation and progression of breast cancer. J Pathol 2015; 236: 90-102.
44. Wu L, Timmers C, Maiti B, et al., The E2F1-3 transcription factors are essential for cellular proliferation. Nature 2001; 414: 457-62.
45. Xu M, Sheppard KA, Peng CY, et al., Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation. Mol Cell Biol 1994; 14: 8420-31.
46. Fogal V, Hsieh JK, Royer C, et al., Cell cycle-dependent nuclear retention of p53 by E2F1 requires phosphorylation of p53 at Ser315. Embo J 2005; 24: 2768-82.
47. Nip J, Strom DK, Eischen CM, et al., E2F-1 induces the stabilization of p53 but blocks p53-mediated transactivation. Oncogene 2001; 20: 910-20.
48. Zhou Z, Cao JX, Li SY, et al., p53 Suppresses E2F1-dependent PLK1 expression upon DNA damage by forming p53-E2F1-DNA complex. Exp Cell Res 2013; 319: 3104-15.
49. Inoue K, Fry EA., Alterations of p63 and p73 in human cancers. Subcell Biochem 2014; 85: 17-40.
50. Zhang Z, Wang H, Li M, et al., Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene 2005; 24: 7238-47.
51. Kasim V, Huang C, Zhang J, et al., Synergistic cooperation of MDM2 and E2F1 contributes to TAp73 transcriptional activity. Biochem Biophys Res Commun 2014; 449: 319-26.
52. Hayden MS, Ghosh S., Shared principles in NF-kappaB signaling. Cell 2008; 32: 344-62.
53. Koike K, Uchiumi T, Ohga T, et al., Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Lett 1997; 417: 390-4.
54. Ohga T, Uchiumi T, Makino Y, et al., Direct involvement of the YB-1 binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J Biol Chem 1998; 273: 5997-6000.
55. van Roeyen CR, Scurt FG, Brandt S, et al., Cold shock Y-box protein-1 proteolysis autoregulates its transcriptional activities. Cell Commun Signal 2013; 11: 63.
56. Jürchott K, Bergmann S, Stein U, et al., YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J Biol Chem 2003; 278: 27988-96.
57. Basaki Y, Hosoi F, Oda Y, et al., Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells. Oncogene 2007; 26: 2736-46.
58. Berquin IM, Pang B, Dziubinski ML, et al., Ybox-binding protein 1 confers EGF independence to human mammary epithelial cells. Oncogene 2005; 24: 3177-86.
59. Lasham A, Moloney S, Hale T, et al., The Y-box binding protein YB1 is a potential regulator of the p53 tumor suppressor. J Biol Chem 2003; 278: 35516-23.
60. Bargou RC, Jurchott K, Wagener C, et al., Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 1997; 3: 447-50.
61. Astanehe A, Finkbeiner MR, Krzywinski M, et al., MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition. Oncogene 2012; 31: 4434-46.
62. Bergmann S, Royer-Pokora B, Fietze E, et al., YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res 2005; 65: 4078-87.
63. Mertens PR, Steinmann K, Alfonso-Jaume MA, et al., Combinatorial interactions of p53, activating protein-2, and YB-1 with a single enhancer element regulate gelatinase A expression in neoplastic cells. J Biol Chem 2002; 277: 24875-82.
64. Homer C, Knight DA, Hananeia L, et al., Ybox factor YB1 controls p53 apoptotic function. Oncogene 2005; 24: 8314-25.
65. Wan M, Huang W, Kute TE, et al., Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27. Am J Pathol 2012; 180: 2120-33.
66. Joshi B, Rastogi S, Morris M, et al., Differential regulation of human YY1 and caspase 7 promoters by prohibitin through E2F1 and p53 binding sites. Biochem J 2007; 401: 155-66.
67. Donohoe ME, Zhang X, McGinnis L, et al., Targeted disruption of mouse Yin Yang 1 transcription factor results in peri-implantation lethality. Mol Cell Biol 1999; 19: 7237-44.
68. Affar el B, Gay F, Shi Y, et al., Essential dosage-dependent functions of the transcription factor yin yang 1 in late embryonic development and cell cycle progression. Mol Cell Biol 2006; 26: 3565-81.
69. Gronroos E, Terentiev AA, Punga T, et al., YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress. Proc Natl Acad Sci USA 2004; 101: 12165-70.
70. Deng Z, Wan M, Sui G., PIASy-mediated sumoylation of Yin Yang 1 depends on their interaction but not the RING finger. Mol Cell Biol 2007; 27: 3780-92.
71. Ozcan S, Andrali SS, Cantrell JE., Modulation of transcription factor function by O-GlcNAc modification. Biochim Biophys Acta 2010; 1799: 353-64.
72. Ramkumar C, Cui H, Kong Y, et al., Smurf2 suppresses B-cell proliferation and lymphomagenesis by mediating ubiquitination and degradation of YY1. Nat Commun 2013; 4: 2598.
73. Jeong HM, Lee SH, Yum J, et al., Smurf2 regulates the degradation of YY1. Biochim Biophys Acta 2014; 1843: 2005-11.
74. Atchison L, Ghias A, Wilkinson F, et al., Transcription factor YY1 functions as a PcG protein in vivo. Embo J 2003; 22: 1347-58.
75. Wang L, Brown JL, Cao R, et al., Hierarchical recruitment of polycomb group silencing complexes. Mol Cell 2004; 14: 637-646.
76. Wilkinson FH, Park K, Atchison ML., Polycomb recruitment to DNA in vivo by the YY1 REPO domain. Proc Natl Acad Sci USA 2006; 103: 19296-301.
77. Bracken AP, Pasini D, Capra M, et al., EZH2 is downstream of the pRB E2F pathway, essential for proliferation and amplified in cancer. Embo J 2003; 22: 5323-35.
78. Varambally S, Dhanasekaran SM, Zhou M, et al., The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624-9.
79. Simon JA, Lange CA., Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008; 647: 21-9.
80. Berezovska OP, Glinskii AB, Yang Z, et al., Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 2006; 5: 1886-901.
81. Kondo Y., Targeting histone methyltransferase EZH2 as cancer treatment. J Biochem 2014; 156: 249-57.
82. Schlisio S, Halperin T, Vidal M, et al., Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity of E2F function. Embo J 2002; 21: 5775-86.
83. Zingg D, Debbache J, Schaefer SM, et al., The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nat Commun 2015; 6: 6051.
84. Liu G, Xia T, Chen X., The activation domains, the proline-rich domain, and the C-terminal basic domain in p53 are necessary for acetylation of histones on the proximal p21 promoter and interaction with p300/CREB-binding protein. J Biol Chem 2003; 278: 17557-65.
85. Cheng TH, Cohen SN., Human MDM2 isoforms translated differentially on constitutive versus p53-regulated transcripts have distinct functions in the p53/MDM2 and TSG101/MDM2 feedback control loops. Mol Cell Biol 2007; 27: 111-9.